# 1 Novel risk loci for COVID-19 hospitalization among

# 2 admixed American populations

- 3 Silvia Diz-de Almeida, <sup>1,2,13,7</sup> Raquel Cruz, <sup>1,2,13,7</sup> Andre D. Luchessi, <sup>3</sup> José M. Lorenzo-Salazar, <sup>4</sup>
- 4 Miguel López de Heredia,<sup>2</sup> Inés Quintela,<sup>5</sup> Rafaela González-Montelongo,<sup>4</sup> Vivian N. Silbiger,<sup>3</sup>
- 5 Marta Sevilla Porras, <sup>2,6</sup> Jair Antonio Tenorio Castaño, <sup>2,6,7</sup> Julian Nevado, <sup>2,6,7</sup> Jose María
- 6 Aguado, <sup>8,9,10,11</sup> Carlos Aguilar, <sup>12</sup> Sergio Aguilera-Albesa, <sup>13,14</sup> Virginia Almadana, <sup>15</sup> Berta
- 7 Almoguera, <sup>16,2</sup> Nuria Alvarez, <sup>17</sup> Álvaro Andreu-Bernabeu, <sup>18,10</sup> Eunate Arana-Arri, <sup>19,20</sup> Celso
- 8 Arango, <sup>18,21,10</sup> María J. Arranz, <sup>22</sup> Maria-Jesus Artiga, <sup>23</sup> Raúl C. Baptista-Rosas, <sup>24,25,26</sup> María
- 9 Barreda- Sánchez, <sup>27,28</sup> Moncef Belhassen-Garcia, <sup>29,30</sup> Joao F. Bezerra, <sup>31</sup> Marcos A.C. Bezerra, <sup>32</sup>
- Lucía Boix-Palop, <sup>33</sup> María Brion, <sup>34,35</sup> Ramón Brugada, <sup>36,37,35,38</sup> Matilde Bustos, <sup>39</sup> Enrique J.
- 11 Calderón, <sup>39,40,41</sup> Cristina Carbonell, <sup>42,30</sup> Luis Castano, <sup>19,43,2,44,45</sup> Jose E. Castelao, <sup>46</sup> Rosa Conde-
- 12 Vicente, 47 M. Lourdes Cordero-Lorenzana, 48 Jose L. Cortes-Sanchez, 49,50, Marta Corton, 16,2 M.
- 13 Teresa Darnaude, <sup>51</sup> Alba De Martino-Rodríguez, <sup>52,53</sup> Victor del Campo-Pérez, <sup>54</sup> Aranzazu Diaz
- de Bustamante, <sup>51</sup> Elena Domínguez-Garrido, <sup>55</sup> Rocío Eirós, <sup>56</sup> María Carmen Fariñas, <sup>57,58,59</sup>
- María J. Fernandez-Nestosa <sup>60</sup> Uxía Fernández-Robelo, <sup>61</sup> Amanda Fernández-Rodríguez, <sup>62,11</sup>
- Tania Fernández-Villa, <sup>63,41</sup> Manuela Gago-Domínguez, <sup>5,64</sup> Belén Gil-Fournier, <sup>65</sup> Javier Gómez-
- 17 Arrue, <sup>52,53</sup> Beatriz González Álvarez, <sup>52,53</sup> Fernan Gonzalez Bernaldo de Quirós, <sup>66</sup> Anna
- 18 González-Neira, <sup>17</sup> Javier González-Peñas, <sup>18,10,21</sup> Juan F. Gutiérrez-Bautista, <sup>67</sup> María José
- 19 Herrero, <sup>68,69</sup> Antonio Herrero-Gonzalez, <sup>70</sup> María A. Jimenez-Sousa, <sup>62,11</sup> María Claudia Lattig, <sup>71,72</sup>
- 20 Anabel Liger Borja, <sup>73</sup> Rosario Lopez-Rodriguez, <sup>16,2,74</sup> Esther Mancebo, <sup>75,76</sup> Caridad Martín-
- 21 López, <sup>73</sup> Vicente Martín, <sup>63 41</sup> Oscar Martinez-Nieto, <sup>77,72</sup> Iciar Martinez-Lopez, <sup>78,79</sup> Michel F.
- 22 Martinez-Resendez, <sup>49</sup> Ángel Martinez-Perez, <sup>80</sup> Juliana F. Mazzeu, <sup>81,82,83</sup> Eleuterio Merayo
- 23 Macías, <sup>84</sup> Pablo Minguez, <sup>16,2</sup> Victor Moreno Cuerda, <sup>85,86</sup> Silviene F. Oliveira, <sup>87,88,83,89</sup> Eva
- Ortega-Paino, <sup>23</sup> Mara Parellada, <sup>18,21,10</sup> Estela Paz-Artal, <sup>75,76,90</sup> Ney P.C. Santos, <sup>91</sup> Patricia Pérez-
- 25 Matute, <sup>92</sup> Patricia Perez, <sup>93</sup> M. Elena Pérez-Tomás, <sup>27</sup> Teresa Perucho, <sup>94</sup> Mel·lina Pinsach-
- Abuin, <sup>36,35</sup> Guillermo Pita, <sup>17</sup> Ericka N. Pompa-Mera, <sup>95,96</sup> Gloria L. Porras-Hurtado, <sup>97</sup> Aurora

- 27 Pujol, 98,2,99 Soraya Ramiro León, 65 Salvador Resino, 62,11 Marianne R. Fernandes, 91,100 Emilio
- 28 Rodríguez-Ruiz, <sup>101,64</sup> Fernando Rodriguez-Artalejo, <sup>102,103,41,104</sup> José A. Rodriguez-Garcia, <sup>105</sup>
- Francisco Ruiz-Cabello, <sup>67,106,107</sup> Javier Ruiz-Hornillos, <sup>108,109,110</sup> Pablo Ryan, <sup>111,112,113,11</sup> José
- 30 Manuel Soria, 80 Juan Carlos Souto, 114 Eduardo Tamayo, 115,116,11 Alvaro Tamayo-Velasco, 117
- Juan Carlos Taracido-Fernandez, 70 Alejandro Teper, 118 Lilian Torres-Tobar, 119 Miguel
- 32 Urioste, <sup>120</sup> Juan Valencia-Ramos, <sup>121</sup> Zuleima Yáñez, <sup>122</sup> Ruth Zarate, <sup>123</sup> Itziar de Rojas, <sup>124,125</sup>
- 33 Agustín Ruiz, 124,125 Pascual Sánchez, 126 Luis Miguel Real, 127 SCOURGE Cohort Group, Encarna
- Guillen-Navarro, <sup>27,128,129,130</sup> Carmen Ayuso, <sup>16,2</sup> Esteban Parra, <sup>131</sup> José A. Riancho, <sup>57,58,59,2</sup>
- 35 Augusto Rojas-Martinez, <sup>132</sup> Carlos Flores, <sup>4,133,134,135,136</sup>, Pablo Lapunzina, <sup>2,6,7,136</sup> Ángel
- 36 Carracedo, 1,2,5,64,136,\*\*

#### 37 Affiliations

- <sup>1</sup>, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS),
- 39 Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 40 <sup>2</sup>, CIBERER, ISCIII, Madrid, Spain
- 41 <sup>3</sup>, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
- 42 Toxicologicas, Natal, Brazil
- <sup>4</sup>, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife,
- 44 Spain
- 45 <sup>5</sup>, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
- 46 Santiago de Compostela, Spain
- 47 <sup>6</sup>, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
- 48 IDIPAZ, Madrid, Spain
- 49 <sup>7</sup>, ERN-ITHACA-European Reference Network
- 50 8, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
- 51 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- 52 <sup>9</sup>, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
- 53 Salud Carlos III, Madrid, Spain

- 54 <sup>10</sup>, School of Medicine, Universidad Complutense, Madrid, Spain
- 55 <sup>11</sup>, CIBERINFEC, ISCIII, Madrid, Spain
- 56 <sup>12</sup>, Hospital General Santa Bárbara de Soria, Soria, Spain
- 57 <sup>13</sup>, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
- 58 Pamplona, Spain
- 59 14, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 60 <sup>15</sup>, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 61 <sup>16</sup>, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
- 62 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 63 <sup>17</sup>, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- 64 <sup>18</sup>, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
- 65 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 66 <sup>19</sup>, Biocruces Bizkai HRI, Bizkaia, Spain
- 67 <sup>20</sup>, Cruces University Hospital, Osakidetza, Bizkaia, Spain
- 68 <sup>21</sup>, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
- 69 Carlos III, Madrid, Spain
- 70 <sup>22</sup>, Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 71 <sup>23</sup>, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 72 <sup>24</sup>, Hospital General de Occidente, Zapopan Jalisco, Mexico
- 73 <sup>25</sup>, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico
- 74 <sup>26</sup>, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá
- 75 Jalisco, Mexico
- 76 <sup>27</sup>, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- 77 <sup>28</sup>, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- 78 <sup>29</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
- 79 Enfermedades Infecciosas, Salamanca, Spain
- 80 <sup>30</sup>, Universidad de Salamanca, Salamanca, Spain
- 81 <sup>31</sup>. Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Brazil

- 82 <sup>32</sup>, Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 83 <sup>33</sup>, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- 84 <sup>34</sup>, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
- 85 Compostela, Spain
- 86 <sup>35</sup>, CIBERCV, ISCIII, Madrid, Spain
- 87 <sup>36</sup>, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
- 88 Spain
- 89 <sup>37</sup>, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 90 <sup>38</sup>, Hospital Josep Trueta, Cardiology Service, Girona, Spain
- 91 <sup>39</sup>, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 92 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 93 <sup>40</sup>, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
- 94 Seville, Spain
- 95 <sup>41</sup>, CIBERESP, ISCIII, Madrid, Spain
- 96 <sup>42</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
- 97 Spain
- 98 <sup>43</sup>, Osakidetza, Cruces University Hospital, Bizkaia, Spain
- 99 <sup>44</sup>, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
- 100 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 101 <sup>45</sup>, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- 102 <sup>46</sup>, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de
- 103 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 104 <sup>47</sup>, Hospital Universitario Río Hortega, Valladolid, Spain
- 105 <sup>48</sup>, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
- 106 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 107 <sup>49</sup>, Tecnológico de Monterrey, Monterrey, Mexico
- 108 <sup>50</sup>, Otto von Guericke University, Departament of Microgravity and Translational Regenerative
- 109 Medicine, Magdeburg, Germany

- 110 <sup>51</sup>, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain
- 111 <sup>52</sup>, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 112 <sup>53</sup>, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- 113 <sup>54</sup>, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 115 <sup>55</sup>, Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 116 <sup>56</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 117 <sup>57</sup>, IDIVAL, Cantabria, Spain
- 118 <sup>58</sup>, Universidad de Cantabria, Cantabria, Spain
- 119 <sup>59</sup>, Hospital U M Valdecilla, Cantabria, Spain
- 120 <sup>60</sup>, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 121 <sup>61</sup>, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
- 122 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 123 <sup>62</sup>, Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
- de Salud Carlos III (ISCIII), Madrid, Spain
- 125 <sup>63</sup>, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) Instituto de
- 126 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 127 <sup>64</sup>, IDIS
- 128 <sup>65</sup>, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 129 <sup>66</sup>, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 130 <sup>67</sup>, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
- 131 Granada, Spain
- 132 <sup>68</sup>, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 133 <sup>69</sup>, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 134 <sup>70</sup>, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 136 <sup>71</sup>, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia

- 137 <sup>72</sup>, SIGEN Alianza Universidad de los Andes Fundación Santa Fe de Bogotá, Bogotá,
- 138 Colombia
- 139 <sup>73</sup>, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 140 <sup>74</sup>, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización
- 141 Montepríncipe, 28660 Boadilla del Monte, España
- 142 <sup>75</sup>, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 143 <sup>76</sup>, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
- 144 Immunology and Immunodeficiencies Group, Madrid, Spain
- <sup>77</sup>, Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
- 146 <sup>78</sup>, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- <sup>79</sup>, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
- 148 Islas Baleares, Spain
- 149 <sup>80</sup>, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
- 150 Pau, IIB Sant Pau, Barcelona, Spain
- 151 <sup>81</sup>, Universidade de Brasília, Faculdade de Medicina, Brazil
- 152 <sup>82</sup>, Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil
- 153 <sup>83</sup>, Programa de Pós-Graduação em Ciencias da Saude (UnB), Brazil
- 154 <sup>84</sup>, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 155 <sup>85</sup>, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 156 <sup>86</sup>, Universidad Francisco de Vitoria, Madrid, Spain
- 157 <sup>87</sup>, Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
- 158 Brasília, Brazil
- 159 <sup>88</sup>, Programa de Pós-Graduação em Biologia Animal (UnB), Brazil
- 160 <sup>89</sup>, Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil
- 161 <sup>90</sup>, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,
- 162 Madrid, Spain
- 163 <sup>91</sup>, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil

- 164 <sup>92</sup>, Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
- 165 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 166 <sup>93</sup>, Inditex, A Coruña, Spain
- 167 <sup>94</sup>, GENYCA, Madrid, Spain
- 168 <sup>95</sup>, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
- de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 170 <sup>96</sup>, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de
- 171 Infectología, Mexico City, Mexico
- 172 <sup>97</sup>, Clinica Comfamiliar Risaralda, Pereira, Colombia
- 173 <sup>98</sup>, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
- 174 L'Hospitalet de Llobregat, Spain
- 175 <sup>99</sup>, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 176 <sup>100</sup>, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 177 <sup>101</sup>, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
- 178 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 179 logarithment of Preventive Medicine and Public Health, School of Medicine, Universidad
- 180 Autónoma de Madrid, Madrid, Spain
- 181 <sup>103</sup>, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain
- 182 <sup>104</sup>, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 183 <sup>105</sup>, Complejo Asistencial Universitario de León, León, Spain
- 184 <sup>106</sup>, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- 185 <sup>107</sup>, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
- 186 Granada, Spain
- 187 <sup>108</sup>, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 188 <sup>109</sup>, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
- 189 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 190 <sup>110</sup>, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 191 Hospital Universitario Infanta Leonor, Madrid, Spain

- 192 <sup>112</sup>, Complutense University of Madrid, Madrid, Spain
- 193 <sup>113</sup>, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- 194 <sup>114</sup>, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
- 195 Barcelona, Spain
- 196 <sup>115</sup>, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,
- 197 Valladolid, Spain
- 198 <sup>116</sup>, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- 199 <sup>117</sup>, Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,
- 200 Valladolid, Spain
- 201 <sup>118</sup>, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 202 <sup>119</sup>, Fundación Universitaria de Ciencias de la Salud
- 203 <sup>120</sup>, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 204 <sup>121</sup>, University Hospital of Burgos, Burgos, Spain
- 205 <sup>122</sup>, Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 206 <sup>123</sup>, Centro para el Desarrollo de la Investigación Científica, Paraguay
- 207 <sup>124</sup>, Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat
- 208 Internacional de Catalunya, Spain
- 209 <sup>125</sup>, Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
- 210 Instituto de Salud Carlos III, Madrid, Spain
- 211 <sup>126</sup>, CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain
- 212 <sup>127</sup>, Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y
- 213 Microbiología, Sevilla, Spain
- 214 <sup>128</sup>, Sección Genética Médica Servicio de Pediatría, Hospital Clínico Universitario Virgen de la
- 215 Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- 216 <sup>129</sup>, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
- 217 Universidad de Murcia (UMU), Murcia, Spain
- 218 <sup>130</sup>, Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases
- 219 (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

221

222

223

224

225

226

227

228

229

231

232

234

235

236

237

238

242

244

<sup>131</sup> Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario, Canada. 132. Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico 133, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain <sup>134</sup>, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain 135, Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain <sup>136</sup>, These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo 137, These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz 230 \*Correspondence: \*\*Correspondence: angel.carracedo@usc.es 233 **Abstract** The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we 239 conducted a GWAS for COVID-19 hospitalization in admixed Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and seven other participating 240 studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide 241 significant associations, two of which constitute novel loci and were first discovered in 243 Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.

#### Introduction

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

To date, more than 50 loci associated with COVID-19 susceptibility, hospitalization, and severity have been identified using genome-wide association studies (GWAS)<sup>1,2</sup>. The COVID-19 Host Genetics Initiative (HGI) has made significant efforts<sup>3</sup> to augment the power to identify disease loci by recruiting individuals from diverse populations and conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and a focus on cases of European ancestries still predominate in the studies<sup>4,5</sup>. In addition, while trans-ancestry meta-analyses are a powerful approach for discovering shared genetic risk variants with similar effects across populations<sup>6</sup>, they may fail to identify risk variants that have larger effects on particular underrepresented populations. Genetic disease risk has been shaped by the particular evolutionary history of populations and environmental exposures<sup>7</sup>. Their action is particularly important for infectious diseases due to the selective constraints that are imposed by host pathogen interactions<sup>8,9</sup>. Literature examples of this in COVID-19 severity include a DOCK2 gene variant in East Asians<sup>10</sup> and frequent loss-of-function variants in *IFNAR1* and *IFNAR2* genes in Polynesian and Inuit populations, respectively<sup>11,12</sup>. Including diverse populations in case | control GWAS studies with unrelated participants usually requires a prior classification of individuals in genetically homogeneous groups, which are typically analyzed separately to control the population stratification effects<sup>13</sup>. Populations with recent admixture impose an additional challenge to GWASs due to their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the development of alternative approaches and a careful inspection of results to reduce false positives due to population structure<sup>7</sup>. In fact, there are benefits in study power from modeling the admixed ancestries either locally, at the regional scale in the chromosomes, or globally, across the genome, depending on factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry strata<sup>14</sup>. Despite the development of novel methods specifically tailored for the analysis of admixed populations<sup>15</sup>, the lack of a standardized analysis framework and the difficulties in confidently clustering admixed individuals into particular genetic groups often leads to their exclusion from GWAS. The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE) recruited COVID-19 patients between March and December 2020 from hospitals across Spain and from March 2020 to July 2021 in Latin America (https://www.scourge-covid.org). A first GWAS of COVID-19 severity among Spanish patients of European descent revealed novel disease loci and explored age- and sexvarying effects of genetic factors 16. Here, we present the findings of a GWAS metaanalysis in admixed Latin American (AMR) populations, comprising individuals from the SCOURGE Latin-American cohort and the HGI studies, which allowed us to identify two novel severe COVID-19 loci, BAZ2B and DDIAS. Further analyses modeling the admixture from three genetic ancestral components and performing a trans-ethnic meta-analysis led to the identification of an additional risk locus near CREBBP. We finally assessed a cross-ancestry polygenic risk score model with variants associated with critical COVID-19.

#### **Results**

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

### Meta-analysis of COVID-19 hospitalization in admixed Americans

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Study cohorts Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887 controls (not hospitalized COVID-19 patients) from Latin American countries and from recruitments of individuals of Latin American descent conducted in Spain (Supplementary Table 1). Quality control details and estimation of global genetic inferred ancestry (GIA) (Supplementary Figure 1) are described in Methods, whereas clinical and demographic characteristics of patients included in the analysis are shown in Table 1. Summary statistics from the SCOURGE cohort were obtained under a logistic mixed model with the SAIGE model (Methods). Another seven studies participating in the COVID-19 HGI consortium were included in the meta-analysis of COVID-19 hospitalization in admixed Americans (Figure 1). **GWAS** meta-analysis We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as weights for the overlapping markers. The combined GWAS sample size consisted of 4,702 admixed AMR hospitalized cases and 68,573 controls. This GWAS meta-analysis revealed genome-wide significant associations at four risk loci (Table 2, Figure 2), two of which (BAZ2B and DDIAS) were novel discoveries. Four lead variants were identified, linked to other 310 variants (Supplementary Tables 2-3). A gene-based association test revealed a significant association in BAZ2B and in previously known COVID-19 risk loci: LZTFL1, XCR1, FYCO1, CCR9, and IFNAR2 (Supplementary Table 4). Located within the BAZ2B gene, the sentinel variant rs13003835 is an intronic variant associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20, 95% Confidence Interval [CI]=1.12-1.27, p=3.66x10<sup>-8</sup>). This association was not

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

previously reported in any GWAS of COVID-19 published to date. Interestingly, rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry meta-analysis including the five population groups<sup>1</sup>. The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic variant located in chromosome 11 within DDIAS and associated with the risk of COVID-19 hospitalization (OR=2.27, 95% CI=1.70-3.04, p= $2.26 \times 10^{-8}$ ). We also observed a suggestive association with rs2601183 in chromosome 15, which is located between ZNF774 and IOGAP1 (allele-G OR=1.20, 95% CI=1.12-1.29, p=6.11x10<sup>-8</sup>, see Supplementary Table 2), which has not yet been reported in any other GWAS of COVID-19 to date. The GWAS meta-analysis also pinpointed two significant variants at known loci, LZTFL1 and FOXP4. The SNP rs35731912 was previously associated with COVID-19 severity in EUR populations<sup>17</sup>, and it was mapped to LZTFL1. While rs2477820 is a novel risk variant within the FOXP4 gene, it has a moderate LD ( $r^2$ =0.295) with rs2496644, which has been linked to COVID-19 hospitalization<sup>18</sup>. This is consistent with the effects of LD in tag-SNPs when conducting GWAS in diverse populations. None of the lead variants was associated with the comorbidities included in Table 1. **Functional mapping of novel risk variants** Variants belonging to the lead loci were prioritized by positional and expression quantitative trait loci (eOTL) mapping with FUMA, resulting in 31 mapped genes (Supplementary Table 5). Within the region surrounding the lead variant in chromosome 2, FUMA prioritized four genes in addition to BAZ2B (PLA2R1, LY75, WDSUB1, and CD302). rs13003835 (allele C) is an eQTL of LY75 in the esophagus mucosa (NES=0.27) and of BAZ2B-AS in whole blood (NES=0.27), while rs2884110

 $(R^2=0.85)$  is an eQTL of LY75 in lung (NES=0.22). As for the chromosome 11, 343 rs77599934 (allele G) is in moderate-to-strong LD ( $r^2$ =0.776) with rs60606421 (G 344 345 deletion, allele -) which is an eQTL associated with a reduced expression of DDIAS in 346 the lungs (NES=-0.49, allele -). Associations with expression are shown in the 347 supplementary Figure 4. The sentinel variant for the region in chromosome 16 is in perfect LD ( $r^2=1$ ) with rs601183, an eQTL of ZNF774 in the lung. 348 349 Bayesian fine mapping 350 We performed different approaches to narrow down the prioritized loci to a set of most 351 likely genes driving the associations. First, we computed credible sets at the 95% 352 confidence level for causal variants and annotated them with VEP (and V2G aggregate 353 scoring. The 95% confidence credible set from the region of chromosome 2 around 354 rs13003835 included 76 variants, which can be found in the Supplementary Table 6 (VEP and V2G annotations are included in the Supplementary Tables 7 and 8). The V2G 355 356 score prioritized BAZ2B as the most likely gene driving the association. However, the 357 approach was unable to converge allocating variants in a 95% confidence credible set for the region in chromosome 11. 358 359 *Transcriptome-wide association study (TWAS)* Five novel genes, namely, SLC25A37, SMARCC1, CAMP, TYW3, and S100A12 360 361 (supplementary Table 9), were found to be significantly associated in the cross-tissue TWAS. To our knowledge, these genes have not been reported previously in any 362 363 COVID-19 TWAS or GWAS analyses published to date. In the single tissue analyses, 364 ATP50 and CXCR6 were significantly associated in the lungs, CCR9 was significantly 365 associated in whole blood, and IFNAR2 and SLC25A37 were associated in lymphocytes.

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

Likewise, we carried out TWAS analyses using the models trained in the admixed populations. However, no significant gene pairs were detected in this case. The top 10 genes with the lowest p-values for each of the datasets (Puerto-Ricans, Mexicans, African-Americans and pooled cohorts) are shown in the Supplementary Table 10. Although not significant, KCNC3 was repeated in the four analyses, whereas MAPKAPK3, NAPSA and THAP5 were repeated in 3 out of 4. Both NAPSA and KCNC3 are located in the chromosome 19 and were reported in the latest HGI meta-analysis<sup>19</sup>. All mapped genes from analyses conducted in AMR populations are shown in Figure 5. Genetic architecture of COVID-19 hospitalization in AMR populations Allele frequencies of rs13003835 and rs77599934 across ancestries Neither rs13003835 (BAZ2B) nor rs77599934 (DDIAS) were significantly associated in the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus, we investigated their allele frequencies (AF) across populations and compared their effect sizes. According to gnomAD v3.1.2, the T allele at rs13003835 (BAZ2B) has an AF of 43% in admixed AMR groups, while AF is lower in the EUR populations (16%) and in the global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that within the Native-American component, the risk allele T is the major allele, whereas it is the minor allele within the African and European LAI components. These large differences in AF might be the reason underlying the association found in AMR populations. However, when comparing effect sizes between populations, we found that they were in opposite directions between SAS-AMR and EUR-AFR-EAS and that there was large heterogeneity among them (Figure 3). We queried SNPs within 50kb

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

windows of the lead variant in each of the other populations that had p-value<0.01. The variant with the lowest p-value in the EUR population was rs559179177 (p=1.72x10<sup>-4</sup>), which is in perfect LD  $(r^2=1)$  in the 1KGP EUR population with our sentinel variant (rs13003835), and in moderate LD  $r^2$ =0.4 in AMR populations. Since this variant was absent from the AMR analysis, probably due to its low frequency, it could not be metaanalyzed. Power calculations revealed that the EUR analysis was underpowered for this variant to achieve genome-wide significance (77.6%, assuming an effect size of 0.46, EAF= 0.0027, and number of cases/controls as shown in the HGI website for B2-EUR). In the cross-population meta-analysis (B2-ALL), rs559179177 obtained a p-value of  $5.9 \times 10^{-4}$ . rs77599934 (DDIAS) had an AF of 1.1% for the G allele in the nonhospitalized controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR groups. This variant has the potential to be a population-specific variant, given the allele frequencies in other population groups, such as EUR (0% in Finnish, 0.025% in non-Finnish), EAS (0%) and SAS (0.042%), and its greater effect size over AFR populations (Figure 3). Examining the LAI, the G allele occurs at a 10.8% frequency in the African component, while it is almost absent in the Native-American and European. Due to its low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population meta-analysis and was only present in the HGI B2 AFR population-specific metaanalysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19 HGI cross-population analysis to investigate whether it was in moderate-to-strong LD with our sentinel variant. The variant with the smallest p-value was rs75684040 (OR=1.07, 95% CI=1.03-1.12, p=1.84x10<sup>-3</sup>). However, LD calculations using the 1KGP phase 3 dataset indicated that rs77599934 and rs75684040 were poorly correlated

 $(r^2=0.11)$ . As for AFR populations, the variant with the lowest p-value was rs138860115 415  $(p=8.3\times10^{-3})$ , but it was not correlated with the lead SNP of this locus. 416 417 418 *Cross-population meta-analyses* We carried out two cross-ancestry inverse variance-weighted fixed-effects meta-419 analyses with the admixed AMR GWAS meta-analysis results to evaluate whether the 420 421 discovered risk loci replicated when considering other population groups. In doing so, 422 we also identified novel cross-population COVID-19 hospitalization risk loci. 423 First, we combined the SCOURGE Latin American GWAS results with the HGI B2 424 ALL analysis (supplementary Table 11). We refer to this analysis as the SC-HGI<sub>ALL</sub> meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19 425 hospitalization in the last HGI release<sup>1</sup>, this study replicated 39, and the association was 426 427 stronger than in the original study in 29 of those (supplementary Table 12). However, the variant rs13003835 located in BAZ2B did not replicate (OR=1.00, 95% CI=0.98-428 1.03, p=0.644). 429 430 In this cross-ancestry meta-analysis, we replicated two associations that were not found in HGIv7, albeit they were sentinel variants in the latest GenOMICC meta-analysis<sup>2</sup>. 431 432 We found an association at the CASC20 locus led by the variant rs2876034 (OR=0.95, 95% CI=0.93-0.97, p=2.83x10<sup>-8</sup>). This variant is in strong LD with the sentinel variant 433 of that study (rs2326788,  $r^2$ =0.92), which was associated with critical COVID-19<sup>2</sup>. In 434 addition, this meta-analysis identified the variant rs66833742 near ZBTB7A associated 435 with COVID-19 hospitalization (OR=0.94, 95% CI=0.92-0.96, p=2.50x10<sup>-8</sup>). Notably, 436 rs66833742 or its perfect proxy rs67602344 (r<sup>2</sup>=1) are also associated with upregulation 437

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

of ZBTB7A in whole blood and in esophageal mucosa. This variant was previously associated with COVID-19 hospitalization<sup>2</sup>. In a second analysis, we also explored the associations across the defined admixed AMR, EUR, and AFR ancestral sources by combining through meta-analysis the SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and admixed AMR and excluding those from EAS and SAS (supplementary Table 13). We refer to this as the SC-HGI<sub>3POP</sub> meta-analysis. The association at rs13003835 (BAZ2B, OR=1.01, 95% CI=0.98-1.03, p=0.605) was not replicated, and rs77599934 near *DDIAS* could not be assessed, although the association at the ZBTB7A locus was confirmed  $(rs66833742, OR=0.94, 95\% CI=0.92-0.96, p=1.89x10^{-8})$ . The variant rs76564172 located near CREBBP also reached statistical significance (OR=1.31, 95% CI=1.25-1.38, p=9.64x10<sup>-9</sup>). The sentinel variant of the region linked to *CREBBP* (in the transancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary Table 6). Eight variants were included in the credible set for the region in chromosome 16 (meta-analysis SC-HGI<sub>3POP</sub>). Polygenic risk score models Using the 49 variants associated with disease severity that are shared across populations according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its generalizability in the admixed AMR (supplementary Table 14). First, we calculated the PGS for the SCOURGE Latin Americans and explored the association with COVID-19 hospitalization under a logistic regression model. The PGS model was associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS standard deviation. It also contributed to explaining a slightly larger variance ( $\Delta R2=1.07\%$ ) than the baseline model.

Subsequently, we divided the individuals into PGS deciles and percentiles to assess their risk stratification. The median percentile among controls was 40, while in cases, it was 63. Those in the top PGS decile exhibited a 2.89-fold (95% CI=2.37-3.54, p=1.29x10<sup>-7</sup>) greater risk compared to individuals in the deciles between 4 and 6 (corresponding to a score of the median distribution). We also examined the distribution of PGS scores across a 5-level severity scale to further determine if there was any correspondence between clinical severity and genetic risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas higher median scores were observed in the moderate, severe, and critical patients (Figure 4). We fitted a multinomial model using the asymptomatic class as a reference and calculated the OR for each category (supplementary Table 15), observing that the disease genetic risk was similar among asymptomatic, mild, and moderate patients. Given that the PGS was built with variants associated with critical disease and/or hospitalization and that the categories severe and critical correspond to hospitalized patients, these results underscore the ability of cross-ancestry PGS for risk stratification even in an admixed population.

### **DISCUSSION**

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely shared among populations, trans-ancestry meta-analyses on this disease have primarily included EUR samples. This dominance of GWAS in Europeans and the subsequent bias in sample sizes can mask population-specific genetic risks (i.e., variants that are monomorphic in some populations) or be less powered to detect risk variants having

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

higher allele frequencies in population groups other than Europeans. In this sense, after combining data from admixed AMR patients, we found two risk loci that were first discovered in a GWAS of Latin American populations. Interestingly, the sentinel variant rs77599934 in the DDIAS gene is a rare coding variant (~1% for allele G) with a large effect on COVID-19 hospitalization that is nearly monomorphic in most of the other populations. This has likely led to its exclusion from the cross-population metaanalyses conducted to date, remaining undetectable. Fine mapping of the region harboring DDIAS did not reveal further information about which gene could be the more prone to be causal or about the functional consequences of the risk variant, but our sentinel variant was in strong LD with an eOTL that associated with reduced gene expression of DDIAS in the lung. DDIAS, known as damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has been linked to DNA damage repair mechanisms: research has shown that depletion of DDIAS leads to an increase in ATM phosphorylation and the formation of p53-binding protein (53BP1) foci, a known biomarker of DNA double-strand breaks, suggesting a potential role in double-strand break repair<sup>20</sup>. Interestingly, a study found that infection by SARS-CoV-2 also triggered the phosphorylation of ATM kinase and inhibited repair mechanisms, causing the accumulation of DNA damage<sup>21</sup>. This gene has also been proposed as a potential biomarker for lung cancer after finding that it interacts with STAT3 in lung cancer cells, regulating IL-6<sup>22,23</sup> and thus mediating inflammatory processes, while another study determined that its blockade inhibited lung cancer cell growth<sup>24</sup>. Another prioritized gene from this region was *PRCP*, an angiotensinase which shares substrate specificity with ACE2 receptor. It has been positively linked to hypertension and some studies have raised hypotheses on its role in COVID-19 progression, particularly in relation to the development of pro-thrombotic events <sup>25,26</sup>.

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

The risk region found in chromosome 2 harbors more than one gene. The lead variant rs13003835 is located within BAZ2B, and it increases the expression of the antisense BAZ2B gene in whole blood. BAZ2B encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers<sup>27</sup> constituting the BRF-1/BRF-5 complexes with SMARCA1 and SMARCA5, respectively. Interestingly, it was discovered that Inc-BAZ2B promotes macrophage activation through regulation of BAZ2B expression. Its over-expression resulted in pulmonary inflammation and elevated levels of MUC5AC in mice with asthma<sup>28</sup>. This variant was also an eQTL for LY75 (encoding lymphocyte antigen 75) in the esophageal mucosa tissue. Lymphocyte antigen 75 is involved in immune processes through antigen presentation in dendritic cells and endocytosis<sup>29</sup> and has been associated with inflammatory diseases, representing a compelling candidate for the region. Increased expression of LY75 has been detected within hours after infection by SARS-CoV-2<sup>30,31</sup>. It is worth noting that differences in AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific studies. A third novel risk region was observed on chromosome 15 between the IOGAP1 and ZNF774 genes, although it did not reach genome-wide significance. Secondary analyses revealed five TWAS-associated genes, some of which have already been linked to severe COVID-19. In a comprehensive multitissue gene expression profiling study<sup>32</sup>, decreased expression of *CAMP* and *S100A8/S100A9* genes in patients with severe COVID-19 was observed, while another study detected the upregulation of SCL25A37 among patients with severe COVID-19<sup>33</sup>. SMARCC1 is a subunit of the SWI/SNF chromatin remodeling complex that has been identified as proviral for SARS-CoV-2 and other coronavirus strains through a genome-wide screen<sup>34</sup>. This complex is

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

crucial for ACE2 expression and viral entry into the cell<sup>35</sup>. However, it should be noted that using eQTL mostly from European populations such as those in GTEx could result in reduced power to detect associations. To explore the genetic architecture of the trait among admixed AMR populations, we performed two cross-ancestry meta-analyses including the SCOURGE Latin American cohort GWAS findings. We found that the two novel risk variants were not associated with COVID-19 hospitalization outside the population-specific meta-analysis, highlighting the importance of complementing trans-ancestry meta-analyses with groupspecific analyses. Notably, this analysis did not replicate the association at the DSTYK locus, which was associated with severe COVID-19 in Brazilian individuals with higher European admixture<sup>36</sup>. This lack of replication aligns with the initial hypothesis of that study suggesting that the risk haplotype was derived from European populations, as we reduced the weight of this ancestral contribution in our study by excluding those individuals. Moreover, these cross-ancestry meta-analyses pointed to three loci that were not genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at CREBBP and two loci at ZBTB7A and CASC20 that were reported in another meta-analysis. CREBBP and ZBTB7A achieved a stronger significance when considering only the EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of the ZBTB7A gene promote a quasihomeostatic state between coronaviruses and host cells, preventing cell death by regulating oxidative stress pathways<sup>37</sup>. This gene is involved in several signaling pathways, such as B and T-cell differentiation<sup>38</sup>. On a separate note, CREBBP encodes the CREB binding protein (CBP), which is involved in transcriptional activation and is known to positively regulate the type I interferon response through virus-induced phosphorylation of IRF-3<sup>39</sup>. In addition, the

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

CREBP/CBP interaction has been implicated in SARS-CoV-2 infection 40 via the cAMP/PKA pathway. In fact, cells with suppressed CREBBP gene expression exhibit reduced replication of the so-called Delta and Omicron SARS-CoV-2 variants<sup>40</sup>. We developed a cross-population PGS model, which effectively stratified individuals based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. Only a few polygenic scores were derived from COVID-19 GWAS data. Horowitz et al. (2022)<sup>41</sup> developed a score using 6 and 12 associated variants (PGS ID: PGP000302) and reported an associated OR (top 10% vs rest) of 1.38 for risk of hospitalization in European populations, whereas the OR for Latin-American populations was 1.56. Since their sample size and the number of variants included in the PGS were lower, direct comparisons are not straightforward. Nevertheless, our analysis provides the first results for a PRS applied to a relatively large AMR cohort, being of value for future analyses regarding PRS transferability. This study is subject to limitations, mostly concerning sample recruitment and composition. The SCOURGE Latino-American sample size is small, and the GWAS is likely underpowered. Another limitation is the difference in case \( \subseteq \) control recruitment across sampling regions that, yet controlled for, may reduce the ability to observe significant associations driven by different compositions of the populations. In this sense, the identified risk loci might not replicate in a cohort lacking any of the parental population sources from the three-way admixture. Likewise, we could not explicitly control for socioenvironmental factors that could have affected COVID-19 spread and hospitalization rates, although genetic principal components are known to capture nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We used all the available GWAS data for COVID-19 hospitalization in admixed AMR in this meta-analysis due to the low number of studies conducted. Therefore, we had no

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

studies to replicate or validate the results. These concerns may be addressed in the future by including more AMR GWAS in the meta-analysis, both by involving diverse populations in study designs and by supporting research from countries in Latin America. This study provides novel insights into the genetic basis of COVID-19 severity, emphasizing the importance of considering host genetic factors by using non-European populations, especially of admixed sources. Such complementary efforts can pin down new variants and increase our knowledge on the host genetic factors of severe COVID-19. Materials and methods **GWAS in Latin Americans from SCOURGE** The SCOURGE Latin American cohort A total of 3,729 COVID-19-positive cases were recruited across five countries from Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating centers (supplementary Table 1) from March 2020 to July 2021. In addition, we included 1,082 COVID-19-positive individuals recruited between March and December 2020 in Spain who either had evidence of origin from a Latin American country or showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05% SAS/EAS). These individuals were excluded from a previous SCOURGE study that focused on participants with European genetic ancestries<sup>16</sup>. We used hospitalization as a proxy for disease severity and defined COVID-19-positive patients who underwent hospitalization as a consequence of the infection as cases and those who did not need hospitalization due to COVID-19 as controls.

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

Samples and data were collected with informed consent after the approval of the Ethics and Scientific Committees from the participating centers and by the Galician Ethics Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City) was approved by the National Committee of Clinical Research from Instituto Mexicano del Seguro Social, Mexico (protocol R-2020-785-082). Samples and data were processed following normalized procedures. The REDCap electronic data capture tool<sup>42,43</sup>, hosted at Centro de Investigación Biomédica en Red (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage demographic, epidemiological, and clinical variables. Subjects were diagnosed with COVID-19 based on quantitative PCR tests (79.3%) or according to clinical (2.2%) or laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%). SNP array genotyping Genomic DNA was obtained from peripheral blood and isolated using the Chemagic DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the manufacturer's recommendations. Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher Scientific) following the manufacturer's instructions in the Santiago de Compostela Node of the National Genotyping Center (CeGen-ISCIII; http://www.usc.es/cegen). This array contains probes for genotyping a total of 757,836 SNPs. Clustering and genotype calling were performed using Axiom Analysis Suite v4.0.3.3 software. Quality control steps and variant imputation A quality control (QC) procedure using PLINK 1.9<sup>44</sup> was applied to both samples and the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) <1%, a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

expectations ( $p<1x10^{-6}$ ) with mid-p adjustment. We also explored the excess of heterozygosity to discard potential cross-sample contamination. Samples missing >2% of the variants were filtered out. Subsequently, we kept the autosomal SNPs, removed high-LD regions and conducted LD pruning (windows of 1,000 SNPs, with a step size of 80 and a r<sup>2</sup> threshold of 0.1) to assess kinship and estimate the global ancestral proportions. Kinship was evaluated based on IBD values, removing one individual from each pair with PI HAT>0.25 that showed a Z0, Z1, and Z2 coherent pattern (according to the theoretical expected values for each relatedness level). Genetic principal components (PCs) were calculated with PLINK with the subset of LD pruned variants. Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using the TOPMed Imputation Server, and variants with Rsq<0.3 or with MAF<1% were filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included in the analyses. Genetic admixture estimation Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used reference individuals, was estimated with ADMIXTURE<sup>45</sup> v1.3 software following a two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African (AFR) samples from The 1000 Genomes Project (1KGP)<sup>46</sup> and merged them with the 79 Native American (AMR) samples from Mao et al. 47 keeping the biallelic SNPs. LDpruned variants were selected from this merge using the same parameters as in the QC. We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters and to compose a refined reference for the analyses by applying a threshold of ≥95% of belonging to a particular cluster. As a result, 20 AFR, 18 EUR, and 38 AMR individuals were removed. The same LD-pruned variants data from the remaining individuals were

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

merged with the SCOURGE Latin American cohort to perform supervised clustering and estimate admixture proportions. A total of 471 samples from the SCOURGE cohort with >80% estimated European GIA were removed to reduce the weight of the European ancestral component, leaving a total of 3,512 admixed Latin American (AMR) subjects for downstream analyses. Association analysis The results for the SCOURGE Latin American GWAS were obtained by testing for COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of GIA in the cohort, we opted for a joint testing of all the individuals as a single study using a mixed regression model, as this approach has demonstrated a greater power and sufficient control of population structure<sup>48</sup>. The SCOURGE cohort consisted of 3,512 COVID-19-positive patients: cases (n=1,625) were defined as hospitalized COVID-19 patients, and controls (n=1,887) were defined as nonhospitalized COVID-19-positive patients. Logistic mixed regression models were fitted using the SAIGEgds<sup>49</sup> package in R, which implements the two-step mixed SAIGE<sup>50</sup> model methodology and the SPA test. Baseline covariables included sex, age (continuous), and the first 10 PCs. To account for potential heterogeneity in the recruitment and hospitalization criteria across the participating countries, we adjusted the models by groups of the recruitment areas classified into six categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has not been used in any previously published GWAS of COVID-19. **Meta-analysis of Latin American populations** The results of the SCOURGE Latin American cohort were meta-analyzed with the AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from the public repository (April 8, 2022: https://www.covid19hg.org/results/r7/), summing up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2 phenotype definition because it offered more power, and the presence of population controls not ascertained for COVID-19 does not have a drastic impact on the association results. The meta-analysis was performed using an inverse-variance weighting method in METAL<sup>51</sup>. The average allele frequency was calculated, and variants with low imputation quality (Rsq<0.3) were filtered out, leaving 10,121,172 variants for metaanalysis. Heterogeneity between studies was evaluated with Cochran's Q test. The inflation of results was assessed based on a genomic control (lambda). Replicability of associations The model-based method MAMBA<sup>52</sup> was used to calculate the posterior probabilities of replication for each of the lead variants. Variants with p<1x10<sup>-05</sup> were clumped and combined with random pruned variants from the 1KGP AMR reference panel. Then, MAMBA was applied to the set of significant and non-significant variants. Each of the lead variants was also tested for association with the main comorbidities in the SCOURGE cohort with logistic regression models (adjusted by the same base covariables as the GWAS). Definition of the genetic risk loci and putative functional impact Definition of lead variant and novel loci

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

To define the lead variants in the loci that were genome-wide significant, LD-clumping was performed on the meta-analysis data using a threshold p-value<5x10<sup>-8</sup>, clump distance=1500 kb, independence set at a threshold r<sup>2</sup>=0.1 and the SCOURGE cohort genotype data as the LD reference panel. Independent loci were deemed as a novel finding if they met the following criteria: 1) p-value<5x10<sup>-8</sup> in the meta-analysis and pvalue>5x10<sup>-8</sup> in the HGI B2 ALL meta-analysis or in the HGI B2 AMR and AFR and EUR analyses when considered separately; 2) Cochran's Q-test for heterogeneity of effects is  $<0.05/N_{loci}$ , where  $N_{loci}$  is the number of independent variants with p $<5\times10^{-8}$ ; and 3) the nearest gene has not been previously described in the latest HGIv7 update. Annotation and initial mapping Functional annotation was performed with FUMA<sup>53</sup> for those variants with a pvalue $<5 \times 10^{-8}$  or in moderate-to-strong LD ( $r^2 > 0.6$ ) with the lead variants, where the LD was calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing LD blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA<sup>53</sup>. Gene-based analysis was also performed using MAGMA<sup>54</sup> as implemented in FUMA under the SNP-wide mean model using the 1KGP AMR reference panel. Significance was set at a threshold p<2.66x10<sup>-6</sup> (which assumes that variants can be mapped to a total of 18,817 genes). FUMA allowed us to perform initial gene mapping by two approaches: (1) positional mapping, which assigns variants to genes by physical distance using 10-kb windows; and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes, and esophageal mucosa tissues, establishing a false discovery rate (FDR) of 0.05 to declare significance for variant-gene pairs.

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

Subsequently, to assign the variants to the most likely gene driving the association, we refined the candidate genes by fine mapping the discovered regions Bayesian fine-mapping To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel findings were calculated on the results from each of the three meta-analyses to identify a subset of variants most likely containing the causal variant at the 95% confidence level, assuming that there is a single causal variant and that it has been tested. We used corrcoverage (https://cran.rstudio.com/web/packages/corrcoverage/index.html) for R to calculate the posterior probabilities of the variant being causal for all variants with a r<sup>2</sup>>0.1 with the leading SNP and within 1 Mb except for the novel variant in chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the credible set until the sum of the posterior probabilities was  $\geq 0.95$ . VEP and V2G annotation We used the Variant-to-Gene (V2G) score to prioritize the genes that were most likely affected by the functional evidence based on expression quantitative trait loci (eQTL), chromatin interactions, in silico functional predictions, and distance between the prioritized variants and transcription start site (TSS), based on data from the Open Targets Genetics portal<sup>55</sup>. Details of the data integration and the weighting of each of the datasets are described with detail here: https://genetics-docs.opentargets.org/ourapproach/data-pipeline. V2G is a score for ranking the functional genomics evidence that supports the connection between variants and genes (the higher the score the more likely the variant to be functionally implicated on the assigned gene). We used VEP release 111 (URL: https://www.ensembl.org/info/docs/tools/vep/index.html; accessed

April 10, 2024) <sup>56</sup> to annotate the following: gene symbol, function (exonic, intronic, 750 intergenic, non-coding RNA, etc.), impact, feature type, feature, and biotype. 751 We queried the GWAS Catalog (date of accession: 01/07/2024) for evidence of 752 association of each of the prioritized genes with traits related to lung diseases or 753 754 phenotypes. Lastly, those which were linked to COVID-19, infection, or lung diseases in the revised literature were classified as "literature evidence". 755 Transcription-wide association studies 756 757 Transcriptome-wide association studies (TWAS) were conducted using the pretrained prediction models with MASHR-computed effect sizes on GTEx v8 datasets<sup>57,58</sup>. The 758 759 results from the Latin American meta-analysis were harmonized and integrated with the prediction models through S-PrediXcan<sup>59</sup> for lung, whole blood, lymphocyte and 760 esophageal mucosal tissues. Statistical significance was set at p-value<0.05 divided by 761 the number of genes that were tested for each tissue. Subsequently, we leveraged results 762 for all 49 tissues and ran a multitissue TWAS to improve the power for association, as 763 demonstrated recently<sup>60</sup>. TWAS was also performed using recently published gene 764 expression datasets derived from a cohort of African Americans, Puerto Ricans, and 765 Mexican Americans (GALA II-SAGE)<sup>61</sup>. 766 767 768 **Cross-population meta-analyses** We conducted two additional meta-analyses to investigate the ability of combining 769 770 populations to replicate our discovered risk loci. This methodology enabled the 771 comparison of effects and the significance of associations in the novel risk loci between 772 the results from analyses that included or excluded other population groups.

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

The first meta-analysis comprised the five populations analyzed within HGI (B2-ALL). Additionally, to evaluate the three GIA components within the SCOURGE Latin American cohort<sup>62</sup>, we conducted a meta-analysis of the admixed AMR, EUR, and AFR cohorts (B2). All summary statistics were retrieved from the HGI repository. We applied the same meta-analysis methodology and filters as in the admixed AMR metaanalysis. **Cross-population Polygenic Risk Score** A polygenic risk score (PGS) for critical COVID-19 was derived by combining the variants associated with hospitalization or disease severity that have been discovered to date. We curated a list of lead variants that were 1) associated with either severe disease or hospitalization in the latest HGIv7 release<sup>1</sup> (using the hospitalization weights) or 2) associated with severe disease in the latest GenOMICC meta-analysis<sup>2</sup> that were not reported in the latest HGI release. A total of 48 markers were used in the PGS model (see supplementary Table 13) since two variants were absent from our study. Scores were calculated and normalized for the SCOURGE Latin American cohort with PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization (COVID-19-positive patients who were hospitalized vs. COVID-19-positive patients who did not necessitate hospital admission) by fitting a logistic regression model. Prediction accuracy for the PGS was assessed by performing 500 bootstrap resamples of the increase in the pseudo-R-squared. We also divided the sample into deciles and percentiles to assess risk stratification. The models were fit for the dependent variable adjusting for sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR cohort) with and without the PGS, and the partial pseudo-R2 was computed and averaged among the resamples.

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

A clinical severity scale was used in a multinomial regression model to further evaluate the power of this cross-ancestry PGS for risk stratification. These severity strata were defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3) severe disease, that is, with hospital admission and PaO<sub>2</sub><65 mmHg or SaO<sub>2</sub><90%, PaO<sub>2</sub>/FiO<sub>2</sub><300, SaO<sub>2</sub>/FiO<sub>2</sub><440, dyspnea, respiratory frequency≥22 bpm, and infiltrates affecting >50% of the lungs; and 4) critical disease, that is, with an admission to the ICU or need of mechanical ventilation (invasive or noninvasive). Data availability Summary statistics from the SCOURGE Latin American GWAS and the analysis scripts are available from the public repository https://github.com/CIBERER/Scourge-COVID19. **Funding** Instituto de Salud Carlos III (COV20\_00622 to A.C., COV20/00792 to M.B., COV20\_00181 to C.A., COV20\_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.); European Union (ERDF) 'A way of making Europe'. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19' to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.).

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

https://doi.org/10.1101/2022.12.24.22283874 (2023).

SD-DA was supported by a Xunta de Galicia predoctoral fellowship. **Author contributions** Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis: SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript: SD-DA, RC, ADL, AC, CF, JAR, AR-M, and PL. Approval of the final version of the publication: all coauthors. Acknowledgments The contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures is also acknowledged. The authors are also particularly grateful for the supply of material and the collaboration of patients, health professionals from participating centers and biobanks. Namely, Biobanc-Mur, and biobancs of the Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón, Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN. References Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic architecture of COVID-19. 2022.12.24.22283874 Preprint at

- 845 2. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
- Nature. https://www.nature.com/articles/s41586-023-06034-3.
- 847 3. Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature
- 848 **600**, 472–477 (2021).
- 849 4. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
- 850 (2016).
- 851 5. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
- 852 Studies. Cell 177, 26–31 (2019).
- 853 6. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and
- challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).
- 855 7. Rosenberg, N. A. et al. Genome-wide association studies in diverse populations. Nat.
- 856 Rev. Genet. 11, 356-366 (2010).
- 857 8. Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools,
- insights and translational opportunities. Nat. Rev. Genet. 22, 137–153 (2021).
- 859 9. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious
- disease in human populations. *Nat. Rev. Genet.* **15**, 379–393 (2014).
- Namkoong, H. et al. DOCK2 is involved in the host genetics and biology of severe
- 862 COVID-19. Nature 609, 754-760 (2022).
- 863 11. Bastard, P. et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral
- diseases in homozygotes. J. Exp. Med. 219, e20220028 (2022).
- 865 12. Duncan, C. J. A. et al. Life-threatening viral disease in a novel form of autosomal
- 866 recessive IFNAR2 deficiency in the Arctic. J. Exp. Med. **219**, e20212427 (2022).
- 867 13. Peterson, R. E. et al. Genome-wide Association Studies in Ancestrally Diverse
- 868 Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell 179, 589-603
- 869 (2019).
- 870 14. Mester, R. et al. Impact of cross-ancestry genetic architecture on GWAS in admixed
- 871 populations. 2023.01.20.524946 Preprint at https://doi.org/10.1101/2023.01.20.524946
- 872 (2023).
- 873 15. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and
- to boost power | Nature Genetics. https://www.nature.com/articles/s41588-020-00766-y.
- 875 16. Cruz, R. et al. Novel genes and sex differences in COVID-19 severity. Hum. Mol. Genet.
- 876 **31**, 3789–3806 (2022).
- 877 17. Degenhardt, F. et al. Detailed stratified GWAS analysis for severe COVID-19 in four
- 878 European populations. *Hum. Mol. Genet.* **31**, 3945–3966 (2022).
- 879 18. Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature.
- 880 https://www.nature.com/articles/s41586-022-04576-6.
- 881 19. Kanai, M. et al. A second update on mapping the human genetic architecture of
- 882 COVID-19. Nature **621**, E7-E26 (2023).

- 883 20. Evolution-based screening enables genome-wide prioritization and discovery of DNA
- repair genes | PNAS. https://www.pnas.org/doi/full/10.1073/pnas.1906559116.
- 885 21. Gioia, U. et al. SARS-CoV-2 infection induces DNA damage, through CHK1 degradation
- and impaired 53BP1 recruitment, and cellular senescence. *Nat. Cell Biol.* **25**, 550–564 (2023).
- 887 22. Im, J.-Y. et al. DDIAS promotes STAT3 activation by preventing STAT3 recruitment to
- PTPRM in lung cancer cells. *Oncogenesis* **9**, 1–11 (2020).
- 889 23. Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis
- suppressor, is a potential therapeutic target in cancer. Exp. Mol. Med. 1–7 (2023)
- 891 doi:10.1038/s12276-023-00974-6.
- 892 24. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549
- 893 non-small cell lung carcinoma Won 2014 International Journal of Cancer Wiley Online
- Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600.
- 895 25. Angeli, F. et al. The spike effect of acute respiratory syndrome coronavirus 2 and
- coronavirus disease 2019 vaccines on blood pressure. Eur. J. Intern. Med. 109, 12–21 (2023).
- 897 26. Silva-Aguiar, R. P. et al. Role of the renin-angiotensin system in the development of
- 898 severe COVID-19 in hypertensive patients. Am. J. Physiol.-Lung Cell. Mol. Physiol. 319, L596-
- 899 L602 (2020).
- 27. Li, Y. et al. The emerging role of ISWI chromatin remodeling complexes in cancer. J.
- 901 Exp. Clin. Cancer Res. 40, 346 (2021).
- 902 28. Xia, L. et al. Inc-BAZ2B promotes M2 macrophage activation and inflammation in
- 903 children with asthma through stabilizing BAZ2B pre-mRNA. J. Allergy Clin. Immunol. 147, 921-
- 904 932.e9 (2021).
- 905 29. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance
- 906 Antigen Presentation via Major Histocompatibility Complex Class II-Positive Lysosomal
- 907 Compartments | Journal of Cell Biology | Rockefeller University Press.
- 908 https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-
- 909 Dec.
- 910 30. Sims, A. C. et al. Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear
- 911 Import Block Enhances Host Transcription in Human Lung Cells, J. Virol. 87, 3885–3902 (2013).
- 912 31. A Network Integration Approach to Predict Conserved Regulators Related to
- Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE.
- 914 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374.
- 915 32. Gómez-Carballa, A. et al. A multi-tissue study of immune gene expression profiling
- 916 highlights the key role of the nasal epithelium in COVID-19 severity. Environ. Res. 210, 112890
- 917 (2022).
- 918 33. Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and
- 919 profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-
- 920 CoV-2 oncogenesis mechanism. *Virus Res.* **301**, 198464 (2021).
- 921 34. Wei, J. et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2
- 922 Infection. Cell 184, 76-91.e13 (2021).

- 923 35. Wei, J. et al. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-
- 924 CoV-2 infection. *Nat. Genet.* **55**, 471–483 (2023).
- 925 36. Pereira, A. C. et al. Genetic risk factors and COVID-19 severity in Brazil: results from
- 926 BRACOVID study. Hum. Mol. Genet. 31, 3021-3031 (2022).
- 927 37. Zhu, X. et al. ZBTB7A promotes virus-host homeostasis during human coronavirus 229E
- 928 infection. Cell Rep. 41, 111540 (2022).
- 929 38. Gupta, S. et al. Emerging role of ZBTB7A as an oncogenic driver and transcriptional
- 930 repressor. Cancer Lett. 483, 22-34 (2020).
- 931 39. Yoneyama, M. et al. Direct triggering of the type I interferon system by virus infection:
- 932 activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17, 1087-
- 933 1095 (1998).
- 934 40. Yang, Q. et al. SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-
- 935 dependent pathways. J. Med. Virol. 95, e28383 (2023).
- 936 41. Horowitz, J. E. et al. Genome-wide analysis provides genetic evidence that ACE2
- 937 influences COVID-19 risk and yields risk scores associated with severe disease. Nat. Genet. 54,
- 938 382-392 (2022).
- 939 42. Harris, P. A. et al. Research electronic data capture (REDCap)—A metadata-driven
- methodology and workflow process for providing translational research informatics support. J.
- 941 Biomed. Inform. 42, 377-381 (2009).
- 942 43. Harris, P. A. et al. The REDCap consortium: Building an international community of
- 943 software platform partners. J. Biomed. Inform. 95, 103208 (2019).
- 944 44. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-
- 945 Based Linkage Analyses. Am. J. Hum. Genet. **81**, 559–575 (2007).
- 946 45. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
- 947 unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
- 948 46. Auton, A. et al. A global reference for human genetic variation. Nature **526**, 68–74
- 949 (2015).
- 950 47. Mao, X. et al. A Genomewide Admixture Mapping Panel for Hispanic/Latino
- 951 Populations. Am. J. Hum. Genet. **80**, 1171–1178 (2007).
- 952 48. Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for
- 953 complex traits. *Nature* **570**, 514–518 (2019).
- 954 49. Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS
- 955 with mixed models. *Bioinformatics* **37**, 728–730 (2021).
- 956 50. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample
- 957 relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
- 958 51. METAL: fast and efficient meta-analysis of genomewide association scans |
- 959 Bioinformatics | Oxford Academic.
- 960 https://academic.oup.com/bioinformatics/article/26/17/2190/198154.

- 961 52. McGuire, D. et al. Model-based assessment of replicability for genome-wide
- association meta-analysis. Nat. Commun. 12, 1964 (2021).
- 963 53. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- 964 annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).
- 965 54. MAGMA: Generalized Gene-Set Analysis of GWAS Data | PLOS Computational Biology.
- https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219.
- 967 55. Ghoussaini, M. et al. Open Targets Genetics: systematic identification of trait-
- 968 associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 49,
- 969 D1311-D1320 (2021).
- 970 56. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 971 57. Barbeira, A. N. et al. Exploiting the GTEx resources to decipher the mechanisms at
- 972 GWAS loci. Genome Biol. 22, 49 (2021).
- 973 58. Barbeira, A. N. et al. GWAS and GTEx QTL integration. Zenodo
- 974 https://doi.org/10.5281/zenodo.3518299 (2019).
- 975 59. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene
- 976 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
- 977 60. Barbeira, A. N. et al. Integrating predicted transcriptome from multiple tissues
- 978 improves association detection. PLOS Genet. 15, e1007889 (2019).
- 979 61. Kachuri, L. et al. Gene expression in African Americans, Puerto Ricans and Mexican
- 980 Americans reveals ancestry-specific patterns of genetic architecture. Nat. Genet. 55, 952–963
- 981 (2023).

986

987

988

989

990

991

- 982 62. Genome-wide patterns of population structure and admixture among Hispanic/Latino
- 983 populations | PNAS. https://www.pnas.org/doi/10.1073/pnas.0914618107?url ver=Z39.88-
- 984 2003&rfr\_id=ori:rid:crossref.org&rfr\_dat=cr\_pub%20%200pubmed.

Table 1. Demographic characteristics of the SCOURGE Latin American cohort.

Variable	Non Hospitalized	Hospitalized		
variable	N = 1,887	N = 1,625		
Age – mean years ± SD	39.1 ± 11.9	54.1 ±14.5		
Sex - N (%)				
Female (%)	1253 (66.4)	668 (41.1)		
GIA* – % mean ±SD				
European	54.4 ±16.2	$39.4 \pm 20.7$		
African	$15.3 \pm 12.7$	$9.1 \pm 11.6$		
Native American	$30.3 \pm 19.8$	$51.3 \pm 26.5$		
Comorbidities - N (%)				
Vascular/endocrinological	488 (25.9)	888 (64.5)		
Cardiac	60 (3.2)	151 (9.3)		
Nervous	15 (0.8)	61 (3.8) 33 (2.0)		
Digestive	14 (0.7)			
Onco-hematological	21 (1.1)	48 (3.00)		
Respiratory	76 (4.0)	118 (7.3)		

<sup>\*</sup>Global genetic inferred ancestry.

## Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	EAF cases	EAF controls	Nearest gene	Mamba PIP
rs13003835	2:159407982	T	С	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	BAZ2B	0.30
rs35731912	3:45848457	T	C	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	LZTFL1	0.95

rs2477820	6:41535254	A	T	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	FOXP4-AS1	0.18
rs77599934	11:82906875	G	A	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	DDIAS	0.95

EA: effect allele; NEA: noneffect allele; EAF: effect allele frequency in the SCOURGE study.

Table 3. Novel variants in the SC-HGI<sub>ALL</sub> and SC-HGI<sub>3POP</sub> meta-analyses (with respect to HGIv7). Independent signals after LD clumping.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	Nearest gene	Analysis
rs76564172	16:3892266	T	G	1.31 (1.19-1.44)	9.64E-09	CREBBP	SC-HGI <sub>3POP</sub>
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	1.89E-08	ZBTB7A	SC-HGI <sub>3POP</sub>
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	2.50E-08	ZBTB7A	SC-HGI <sub>ALL</sub>
rs2876034	20:6492834	A	T	0.95 (0.93-0.97)	2.83E-08	CASC20	SC-HGI <sub>ALL</sub>

EA: effect allele; NEA: non-effect allele.

1008 Figure 1. Flow chart of this study.

1002

1003

1004





Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis. Probability thresholds at  $p=5x10^{-8}$  and  $p=5x10^{-5}$  are indicated by the horizontal lines. Genome-wide significant associations with COVID-19 hospitalizations were found on chromosome 2 (within BAZ2B), chromosome 3 (within LZTFL1), chromosome 6 (within FOXP4), and chromosome 11 (within DDIAS). A Quantile Quantile plot is shown in supplementary Figure 2. B) Regional association plots for rs1003835 at chromosome 2 and rs77599934 at chromosome 11; C) Allele frequency distribution across the 1000 Genomes Project populations for the lead variants rs1003835 and rs77599934. Retrieved from *The Geography of Genetic Variants Web* or GGV.








Figure 3. Forest plot showing effect sizes and the corresponding confidence intervals for the sentinel variants identified in the AMR meta-analysis across populations. All beta values with their corresponding CIs were retrieved from the B2 population-specific meta-analysis from the HGI v7 release, except for AMR, for which the beta value and IC from the HGI<sub>AMR</sub>-SCOURGE meta-analysis are represented.




Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group against the lowest risk group (OR-95% CI); (B) Distribution of the PGS scores in each of the severity scale classes. 0-Asymptomatic, 1-Mild disease, 2-Moderate disease, 3-Severe disease, 4-Critical disease.




Figure 5. Summary of the results from gene prioritization strategies used for genetic associations in AMR populations. GWAS catalog association for *BAZ2B-AS* was with FEV/FCV ratio. Literature based evidence is further explored in discussion.

